Erratum to: Management of Fat Accumulation in Patients with HIV Infection

Julian Falutz

Published online: 27 September 2011
© Springer Science+Business Media, LLC 2011

Erratum to: Curr HIV/AIDS Rep (2011) 8:200–208
DOI 10.1007/s11904-011-0087-3

The original version of this article contained errors in Table 1 and Table 2. The data in the Arm 1, Arm 2, and Arm 3 columns of the tables were incorrectly aligned. The correct tables are presented here.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s11904-011-0087-3>.

J. Falutz (✉)
Immunodeficiency Treatment Center,
McGill University Health Center,
Room A5-140 1650 Cedar Avenue Montreal,
Quebec, Canada H3G 1A4
e-mail: julian.falutz@muhc.mcgill.ca

Table 1 DXA-determined trunk fat changes in treatment-naïve HIV patients initiating HAART

Study	HAART	Baseline					Arm 1	Arm 2	Arm 3
		Backbone	Comparators	Duration	N (M:F)	Age, y	CD4	Log ₁₀ V _L	
Jemsek et al. [42], 2006	AZT+3TC	ATV vs EFV	48 weeks	210 (145:55) BMI – 23.5	30	325	4.75	ATV 5.9 kg +4% BL F/U	EFV 6.3 kg +2% –
Carr et al. [40], 2008	TDF+3TC	TPV/r-100 vs TPV/r-200 vs LPV/r	48 weeks	140 (104:36) BMI – 23.1	35	230	5.00	TPV/r-100 7.5 kg –4% BL F/U	TPV/r-200 7.9 kg –2% LPV/r 6.1 kg +12%
McComsey et al. [43], 2009	3TC+D4T	ATV vs ATV/r	96 weeks	200 (143:57)	35	200	5.00	ATV 9.9 kg +15% BL F/U	ATV/r 8.7 kg +18% –
Moyle et al. [41], 2009 (approx.)	TDF+FTC	ATV/r vs LPV/r	96 weeks	224 (153:71) BMI – 23.6	36	264	5.00	ATV/r 6.2 kg +5% BL F/U	LPV/r 7.2 kg +9% –
Boothby et al. [37], 2009	EFV	AZT+3TC vs TDF+FTC	24 weeks	32 (16:16) BMI – 25.1	34	210	4.85	AZT+3TC 8.1 kg +1% BL F/U	TDF+FTC 6.7 kg +21% –
McComsey et al. [38], 2011 ^a	ABC/3TC or TDF/FTC	ATV/r vs EFV	96 weeks	269 (228:41)	38	233	4.60	ATV/r 9.4 kg +36% BL F/U	EFV 9.4 kg +21% –
McComsey et al. [38], 2011 ^a	ATV/r or EFV	ABC/3TC vs TDF/FTC	96 weeks	269 (228:41)	38	233	4.60	ABC/3TC 9.4 kg +28% BL F/U	TDF/FTC 9.4 kg +25% –
Rockstroh et al. [45], 2011 ^a	TDF/FTC	RAL vs EFV	156 weeks	112 (99:13)	37	230	4.94	RAL 11.0 kg +21% BL F/U	EFV 10.0 kg +38% –

^a Data extracted from conference poster or oral presentation3TC lamivudine, ABC abacavir, ATV atazanavir, AZT zidovudine, BMI body mass index, D4T stavudine, DXA dual energy absorptiometry, EFV efavirenz, FTC emtricitabine, F/U follow-up, HAART highly active antiretroviral therapy, LPV lopinavir, RAL raltegravir, TDF tenofovir, TPV tipranavir, V_L HIV viral load

Table 2 CT-determined visceral adipose tissue changes in treatment-naïve HIV patients initiating HAART

Study	HAART	Baseline					Arm 1	Arm 2	Arm 3
		Comparators	Duration	N (M:F)	Age	CD4	Log ₁₀ V _L		
Jemsek et al. [42], 2006	AZT/3TC	ATV vs EFV	48 weeks	210 (145:55) BMI – 23.5	30	325	4.75	ATV 54 cm ² +40%	EFV 57 cm ² +22%
Carr et al. [40], 2008	TDF+3TC	TPV/r-100 vs TPV/r-200 vs LPV/r	48 weeks	140 (102:36) BMI – 23.1	35	230	5.00	TPV/r-100 72 cm ² –8%	TPV/r-200 63 cm ² –14%
McComsey et al. [43], 2009	3TC+D4T	ATV vs ATV/r	96 weeks	200 (143:57)	35	200	5.00	ATV na +33%	ATV/r na +32%
Moyle et al. [41], 2009 ^a	TDF+FTC	ATV/r vs LPV/r	96 weeks	224 (153:71) BMI – 23.6	36	204	5.00	ATV/r 85 cm ² +15%	LPV/r 85 cm ² +10%
Boothby et al. [37], 2009	EFV	AZT+3TC vs TDF+FTC	24 weeks	32 (16:16) BMI – 25.1	34	210	4.85	AZT+3TC 39 cm ² +73%	TDF+FTC 56 cm ² +28%
McComsey et al. [38], 2011 ^a	ABC/3TC or TDF/FTC	ATV/r vs EFV	96 weeks	269 (228:41)	38	233	4.60	ATV/r 84 cm ² +27%	EFV 84 cm ² +12%
McComsey et al. [38], 2011 ^a	ATV/r or EFV	ABC/3TC vs TDF/FTC	96 weeks	269 (228:41)	38	233	4.60	ABC/3TC 84 cm ² +15%	TDF/FTC 84 cm ² +20%

^a Data extracted from conference poster or oral presentation3TC lamivudine, ABC abacavir, ATV atazanavir, AZT azidothymidine, BL baseline, BMI body mass index, D4T stavudine, EFV efavirenz, FTC emtricitabine, F/U follow-up, HAART highly active antiretroviral therapy, LPV lopinavir, TDF tenofovir, TPV tipranavir, V_L HIV viral load